Literature DB >> 33723061

Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.

Zahra Moghadamchargari1, Mehdi Shirzadeh1, Chang Liu2, Samantha Schrecke1, Charles Packianathan1, David H Russell1, Minglei Zhao2, Arthur Laganowsky3.   

Abstract

Ras is regulated by a specific guanine nucleotide exchange factor Son of Sevenless (SOS), which facilitates the exchange of inactive, GDP-bound Ras with GTP. The catalytic activity of SOS is also allosterically modulated by an active Ras (Ras-GTP). However, it remains poorly understood how oncogenic Ras mutants interact with SOS and modulate its activity. Here, native ion mobility-mass spectrometry is employed to monitor the assembly of the catalytic domain of SOS (SOScat) with KRas and three cancer-associated mutants (G12C, G13D, and Q61H), leading to the discovery of different molecular assemblies and distinct conformers of SOScat engaging KRas. We also find KRasG13D exhibits high affinity for SOScat and is a potent allosteric modulator of its activity. A structure of the KRasG13D•SOScat complex was determined using cryogenic electron microscopy providing insight into the enhanced affinity of the mutant protein. In addition, we find that KRasG13D-GTP can allosterically increase the nucleotide exchange rate of KRas at the active site more than twofold compared to KRas-GTP. Furthermore, small-molecule Ras•SOS disruptors fail to dissociate KRasG13D•SOScat complexes, underscoring the need for more potent disruptors. Taken together, a better understanding of the interaction between oncogenic Ras mutants and SOS will provide avenues for improved therapeutic interventions.

Entities:  

Keywords:  Ras proteins; Ras-SOS; cancer; native mass spectrometry

Mesh:

Substances:

Year:  2021        PMID: 33723061      PMCID: PMC8000204          DOI: 10.1073/pnas.2022403118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  50 in total

Review 1.  The power of ion mobility-mass spectrometry for structural characterization and the study of conformational dynamics.

Authors:  Francesco Lanucara; Stephen W Holman; Christopher J Gray; Claire E Eyers
Journal:  Nat Chem       Date:  2014-04       Impact factor: 24.427

2.  Evidence for Many Unique Solution Structures for Chymotrypsin Inhibitor 2: A Thermodynamic Perspective Derived from vT-ESI-IMS-MS Measurements.

Authors:  Shannon A Raab; Tarick J El-Baba; Daniel W Woodall; Wen Liu; Yang Liu; Zane Baird; David A Hales; Arthur Laganowsky; David H Russell; David E Clemmer
Journal:  J Am Chem Soc       Date:  2020-09-29       Impact factor: 15.419

3.  Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.

Authors:  Zahra Moghadamchargari; Jamison Huddleston; Mehdi Shirzadeh; Xueyun Zheng; David E Clemmer; Frank M Raushel; David H Russell; Arthur Laganowsky
Journal:  Biochemistry       Date:  2019-07-22       Impact factor: 3.162

Review 4.  Sending signals dynamically.

Authors:  Robert G Smock; Lila M Gierasch
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

Review 5.  Human RAS superfamily proteins and related GTPases.

Authors:  John Colicelli
Journal:  Sci STKE       Date:  2004-09-07

6.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.

Authors:  Fumi Shima; Yoko Yoshikawa; Min Ye; Mitsugu Araki; Shigeyuki Matsumoto; Jingling Liao; Lizhi Hu; Takeshi Sugimoto; Yuichi Ijiri; Azusa Takeda; Yuko Nishiyama; Chie Sato; Shin Muraoka; Atsuo Tamura; Tsutomu Osoda; Ken-ichiro Tsuda; Tomoya Miyakawa; Hiroaki Fukunishi; Jiro Shimada; Takashi Kumasaka; Masaki Yamamoto; Tohru Kataoka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

7.  BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

Authors:  Marco H Hofmann; Michael Gmachl; Juergen Ramharter; Fabio Savarese; Daniel Gerlach; Joseph R Marszalek; Michael P Sanderson; Dirk Kessler; Francesca Trapani; Heribert Arnhof; Klaus Rumpel; Dana-Adriana Botesteanu; Peter Ettmayer; Thomas Gerstberger; Christiane Kofink; Tobias Wunberg; Andreas Zoephel; Szu-Chin Fu; Jessica L Teh; Jark Böttcher; Nikolai Pototschnig; Franziska Schachinger; Katharina Schipany; Simone Lieb; Christopher P Vellano; Jonathan C O'Connell; Rachel L Mendes; Jurgen Moll; Mark Petronczki; Timothy P Heffernan; Mark Pearson; Darryl B McConnell; Norbert Kraut
Journal:  Cancer Discov       Date:  2020-08-19       Impact factor: 39.397

8.  Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles.

Authors:  Michael T Marty; Andrew J Baldwin; Erik G Marklund; Georg K A Hochberg; Justin L P Benesch; Carol V Robinson
Journal:  Anal Chem       Date:  2015-04-01       Impact factor: 6.986

9.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

10.  Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras.

Authors:  Sezen Vatansever; Burak Erman; Zeynep H Gümüş
Journal:  Comput Struct Biotechnol J       Date:  2020-04-09       Impact factor: 7.271

View more
  4 in total

1.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Authors:  Christian Johnson; Deborah L Burkhart; Kevin M Haigis
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

2.  Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.

Authors:  Imran Khan; Akiko Koide; Mariyam Zuberi; Gayatri Ketavarapu; Eric Denbaum; Kai Wen Teng; J Matthew Rhett; Russell Spencer-Smith; G Aaron Hobbs; Ernest Ramsay Camp; Shohei Koide; John P O'Bryan
Journal:  Cell Rep       Date:  2022-02-08       Impact factor: 9.423

3.  Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect.

Authors:  Xuan He; Kui Du; Yuanhao Wang; Jigang Fan; Mingyu Li; Duan Ni; Shaoyong Lu; Xiaolan Bian; Yaqin Liu
Journal:  Front Mol Biosci       Date:  2022-04-08

Review 4.  Targeting KRAS mutant cancers: from druggable therapy to drug resistance.

Authors:  Chunxiao Zhu; Xiaoqing Guan; Xinuo Zhang; Xin Luan; Zhengbo Song; Xiangdong Cheng; Weidong Zhang; Jiang-Jiang Qin
Journal:  Mol Cancer       Date:  2022-08-04       Impact factor: 41.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.